A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure

Nephron - Clinical Practice

Volumn 101, Issue 3, 2005, Pages

  MacGregor, Mark S ^a,b,c   Deighan, Christopher J ^a   Rodger, R Stuart C ^b   Boulton Jones, J Michael ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c CROSSHOUSE HOSPITAL   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Calcium channel blockers; Chronic kidney failure; Drug side effects; Hypertension; Proteinuria

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; LOOP DIURETIC AGENT; QUINAPRIL; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DATA ANALYSIS; DEATH; DIALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EDEMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SODIUM RETENTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WATER RETENTION;

ADULT; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAHYDROISOQUINOLINES;

EID: 27544446929     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086714     Document Type: Article

References (39)

1. Mackenzie HS, Taal MW, Luyckx VA, Brenner BM: Adaptation to nephron loss; in Brenner BM (ed): Brenner & Rector's The Kidney, ed 6. Philadelphia, Saunders, 2000, pp 1901-1942.
2. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA: Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003;14:3217-3232.
3. Klahr S, Levey A, Beck J, et al: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-884.
4. Maschio G, Alberti D, Janin G, et al: Effect of the angjotensin- converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945.
5. Zucchelli P, Zuccalà A, Borghi M, et al: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992;42:452-458.
6. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.
7. Hannedouche T, Landais P, Goldfarb B, et al: Randomised controlled trial of enalapril and β blockers in non-diabetic chronic renal failure. BMJ 1994;309:833-837.
8. Himmelmann A, Hansson L, Hansson BG, et al: ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press 1995;4:85-90.
9. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002;136:604-615.
10. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
11. McLaughlin KJ, Harden PN, Ueda S, Boulton-Jones JM, Connell JMC, Jardine AG: The role of genetic polymorphisms of angiotensin-converting enzyme in the progression of renal diseases. Hypertension 1996;28:912-915.
12. Perna A, Ruggenenti P, Testa A, et al: ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 2000;57:274-281.
13. Epstein M: Calcium antagonists and renal disease. Kidney Int 1998;54:1771-1784.
14. Harris DC, Hammond WS, Burke TJ, Schrier RW: Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987;31:41-46.
15. Bianchi S, Bigazzi R, Baldari G, Campese VM: Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up. Am J Nephrol 1991;11:131-137.
16. Okamura M, Kanayama Y, Negoro N, Inoue T, Takeda T: Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy. Contrib Nephrol. Basel, Karger, 1991, vol 90, pp 161-165.
17. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ: Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol. Basel, Karger, 1995, vol 111, pp 184-192.
18. Kanno Y, Suzuki H, Okada H, Takenaka T, Saruta T: Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease. Quart J Med 1996;89:65-70.
19. Acone D, Cante D, Cillo F, Giordano G, Giordano C: Blood pressure and progression of renal failure in the elderly. Kidney Int 1996;49(suppl 55):S75-S77.
20. Pedersen EB, Bech JN, Nielsen CB, et al: A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two years. Scand J Clin Lab Invest 1997;57:673-681.
21. Kumagai H, Hayashi K, Kumamaru H, Saruta T: Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. Am J Hypertens 2000;980-985.
22. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW: Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000;35:427-432.
23. Herlitz H, Harris K, Risler T, et al: The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros study. Nephrol Dial Transplant 2001;16:2158-2165.
24. Petersen LJ, Petersen JR, Talleruphuus U, et al: A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. Clin Nephrol 2001;55:375-383.
25. Rose GW, Kanno Y, Ikebukuro H, et al: Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001;24:377-383.
26. Hayashi K, Kumagai H, Saruta T: Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003;16:116-122.
27. Marin R, Ruilope LM, Aljama P, Aranda P, Segura J, Diez J: A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001;19:1871-1876.
28. Agodoa LY, Appel L, Bakris GL, et al: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. J Am Med Assoc 2001;285:2719-2728.
29. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
30. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG: Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol 2002;13:2125-2132.
31. Klahr S, Breyer JA, Beck GJ, et al: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol 1995;5:2037-2047.
32. Van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RG: No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2003;18:2314-2320.
33. Ruggenenti P, Perna A, Remuzzi G: ACE inhibitors to prevent end-stage renal disease. When to start and why possibly never to stop: a post-hoc analysis of the REIN trial results. J Am Soc Nephrol 2001;12:2832-2837.
34. Payton CD, McLay A, Boulton-Jones JM: Progressive IgA nephropathy: the role of hypertension. Nephrol Dial Transplant 1988;2:138-142.
35. Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: role of blood pressure. Kidney Int 1989;35:670-674.
36. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995;10:1963-1974.
37. Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 1998;9:2096-2101.
38. Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-1289.
39. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-124.